Product logins

Find logins to all Clarivate products below.


Open Surgery Instruments | Market Insights | US | 2022

In 2020, the procedure deferrals due to the COVID-19 pandemic severely impacted the US open surgery instrument market. However, the overall market for open surgery devices in the US will exhibit moderate growth over the forecast period, driven largely by rising penetration of direct energy and closure devices in open procedures as well as the increasing adoption of premium-priced products although rising laparoscopic procedure penetration—and consequently declining open procedure volumes—will hamper market expansion.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for open surgery instruments in the US across an 11-year period.

Related Medtech Insights Reports

Report
ENT Devices – Market Insights – Japan
The Japanese ENT device market is projected to grow at a modest pace over the forecast period, supported by a slight increase in ENT procedure volumes. This growth will be primarily driven by a…
Report
Video and High-Tech Hardware Devices – Market Insights – United States
The US video and high-tech hardware device market will experience modest expansion through 2035. This growth is primarily driven by the increasing adoption of articulated surgical robotic systems…
Report
Laparoscopic Devices – Market Insights – Japan
The Japanese laparoscopic device market will expand modestly through 2035 because demand for MIS procedures will rise in line with the country’s rapidly aging population. The adoption of…
Report
Laparoscopic Devices – Market Insights – Latin America
The Latin American laparoscopic device market will experience steady moderate growth through 2035, supported by the gradual expansion of MIS volumes and selective adoption of highervalue…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Europe
The European GI endoscopy device market will be driven primarily by the high incidence of gastric cancer and CRC in the region. Market growth will be supported by nationwide CRC and GI cancer…